Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Short Interest Update

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) was the recipient of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 173,306 shares, a decline of 34.0% from the July 30th total of 262,477 shares. Based on an average daily volume of 271,752 shares, the short-interest ratio is currently 0.6 days. Currently, 1.4% of the shares of the company are short sold.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP bought a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $34,000. Arax Advisory Partners increased its stake in Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after acquiring an additional 6,173 shares during the period. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $43,000. Finally, HRT Financial LP bought a new stake in shares of Tvardi Therapeutics during the 4th quarter valued at $47,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Stock Performance

Shares of TVRD stock traded down $0.02 on Tuesday, hitting $1.78. The company’s stock had a trading volume of 23,678 shares, compared to its average volume of 917,303. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The company has a market capitalization of $23.69 million, a PE ratio of -0.64 and a beta of 0.39. The stock’s 50 day moving average is $2.30 and its 200-day moving average is $3.02.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, research analysts forecast that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. HC Wainwright assumed coverage on shares of Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. Finally, BTIG Research decreased their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $18.00.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.